MIRASOL试验中米妥昔单抗索拉夫坦辛对比化疗用于叶酸受体α阳性铂耐药卵巢癌患者报告结局:随机、开放标签、3期试验
MIRASOL是一项3期随机开放标签试验,纳入453例叶酸受体α阳性铂耐药卵巢癌患者,比较米妥昔单抗索拉夫坦辛(MIRV)与研究者选择化疗的患者报告结局。第8或9周EORTC QLQ-OV28腹部和胃肠道症状改善率MIRV组34/162(21.0%) vs 化疗组23/150(15.3%),差异无统计学意义(OR 1.5,95%CI 0.8-2.6;P=0.26)。MIRV似乎未损害或改善患者生活质量。
要点
- MIRV组与化疗组第8或9周QLQ-OV28腹部和胃肠道症状改善率分别为21.0%与15.3%,差异无统计学意义。
- MIRV组34例(21.0%)报告改善,化疗组23例(15.3%)报告改善,OR 1.5(95%CI 0.8-2.6;P=0.26)。
- MIRV似乎未损害或改善患者生活质量,两组生活质量结局相似。
核心结论
- 与研究者选择化疗相比,MIRV似乎未损害或改善患者生活质量。
- 两组生活质量结局相似,结合既往报告的MIRV较单药化疗更高的疗效,支持MIRV作为叶酸受体α阳性铂耐药卵巢癌的新治疗选择。
研究设计与样本
- MIRASOL为确证性、3期、随机、对照、开放标签试验,基于此前2期SORAYA试验。
- 纳入18岁及以上、确诊铂耐药复发性高级别浆液性上皮性卵巢癌患者,来自21个国家253个站点(医院、学术中心和社区中心)。
- 患者须接受过1至3线既往系统抗肿瘤治疗,肿瘤叶酸受体α高表达(≥75%肿瘤细胞免疫组化评分≥2+膜染色,PS2+评分法),至少一个可测量病灶,ECOG体能状态0或1。
- 患者按1:1随机分配至MIRV或研究者选择化疗,按既往治疗线数和研究者选择化疗类型分层。
- MIRV静脉给药6 mg/kg(调整理想体重),每3周一次;主要终点为无进展生存期。
主要发现
- 2020年2月3日至2022年8月3日共纳入453例患者,MIRV组227例,研究者选择化疗组226例。
- 所有患者均为女性;301例(66%)为白人,53例(12%)为亚裔,13例(3%)为黑人,86例(19%)为其他种族或未报告;27例(6%)为西班牙裔或拉丁裔。
- 中位随访时间13.1个月(95%CI 12.1-14)。
- QLQ-OV28完成率基线为86%(365/425),第8或9周为81%(282/349)。
- MIRV组162例中34例(21.0%;95%CI 15.0-28.1)报告QLQ-OV28腹部和胃肠道评分改善,研究者选择化疗组150例中23例(15.3%;95%CI 10.0-22.1)报告改善,差异无统计学意义(OR 1.5,95%CI 0.8-2.6;P=0.26)。
关键数值与推荐
- 叶酸受体α高表达定义为≥75%肿瘤细胞免疫组化评分≥2+膜染色(PS2+评分法)。
- MIRV给药剂量为6 mg/kg(调整理想体重),每3周一次,静脉给药。
- 主要终点为无进展生存期;关键次要终点包括客观缓解率、总生存期及第8或9周EORTC QLQ-OV28腹部和胃肠道症状改善≥15.0分(意向治疗人群)。
临床怎么用
- MIRV似乎未损害或改善患者生活质量,两组生活质量结局相似。
- 结合既往报告的MIRV较单药化疗更高的疗效,支持MIRV作为叶酸受体α阳性铂耐药卵巢癌的新治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), approved by the US Food and Drug Administration for the treatment of platinum-resistant ovarian cancer in the USA. Here, we report patient-reported outcomes for participants treated with MIRV compared with investigator's choice of chemotherapy from the phase 3 MIRASOL trial, which met its primary endpoint of progression-free survival and key secondary endpoints of objective response rate and overall survival. METHODS: The MIRASOL trial was a confirmatory, phase 3, randomised, controlled, open-label trial, building on the phase 2 SORAYA trial which had previously demonstrated the safety and efficacy of MIRV in platinum-resistant ovarian cancer. Patients 18 years or older with a confirmed platinum-resistant, recurrent high-grade serous epithelial ovarian cancer diagnosis were recruited from 253 sites including hospitals, academic centres, and community centres in 21 countries. Patients must have received one to three previous systemic anticancer therapies, and have high FRα tumour expression (≥75% tumour cells with an immunohistochemistry score of ≥2+ membrane staining using the PS2+ scoring method), one or more lesions with measurable disease, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) to MIRV or investigator's choice of chemotherapy, stratified by number of previous therapy lines and the type of investigator's choice of chemotherapy. Therapies were administered in an open-label manner; MIRV was administered intravenously at 6 mg/kg of adjusted ideal bodyweight every 3 weeks. The primary endpoint was progression-free survival. Key secondary endpoints were objective response rate, overall survival, and a 15·0-point or greater improvement at week 8 or 9 in abdominal and gastrointestinal symptoms using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Ovarian Cancer Module (EORTC QLQ-OV28) in the intention-to-treat population. The MIRASOL trial was registered at ClinicalTrials.gov (NCT04209855), the Gynecologic Oncology Group (GOG 3045), and the European Network of Gynaecological Oncological Trial Groups (ENGOT-ov55), and is complete. FINDINGS: Between Feb 3, 2020, and Aug 3, 2022, 453 patients were enrolled and randomly assigned to treatment (227 to the MIRV group and 226 to the investigator's choice of chemotherapy group). All patients were female; 301 (66%) participants were White, 53 (12%) were Asian, 13 (3%) were Black, and 86 (19%) were of another race or not reported; 27 (6%) were Hispanic or Latino. The median follow-up for the study, determined by the reverse Kaplan-Meier method, was 13·1 months (95% CI 12·1-14). QLQ-OV28 completion rates were 86% (365 of 425) at baseline and 81% (282 of 349) at week 8 or 9. 34 (21·0%; 95% CI 15·0-28·1) of 162 patients treated with MIRV reported improvement in QLQ-OV28 abdominal and gastrointestinal scores, compared with 23 (15·3%; 10·0-22·1) of 150 patients treated with the investigator's choice of chemotherapy. These differences were not statistically significant (odds ratio 1·5 [95% CI 0·8-2·6]; p=0·26). INTERPRETATION: MIRV did not seem to impair or improve patient quality of life compared with investigator's choice of chemotherapy. The similar quality-of-life outcomes in the two treatment groups, combined with the previously reported higher efficacy of MIRV compared with single-agent chemotherapy, support MIRV as new treatment option for FRα-positive platinum-resistant ovarian cancer. FUNDING: AbbVie.
引用
- Van Gorp T, Moore KN, Konecny GE, et al. Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2025. PMID: 40179908. doi:10.1016/S1470-2045(25)00021-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。